当前位置: 首页 >> 检索结果
65. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
作者: Peter A Noseworthy.;Xiaoxi Yao.;Neena S Abraham.;Lindsey R Sangaralingham.;Robert D McBane.;Nilay D Shah.
来源: Chest. 2016年150卷6期1302-1312页
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians now have a choice between different NOACs, but there is no direct comparative effectiveness evidence to guide decision-making. We aimed to compare the effectiveness and safety of dabigatran, rivaroxaban, and apixaban in clinical practice.
71. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study.
作者: Susan R Kahn.;Andrew M Hirsch.;Arash Akaberi.;Paul Hernandez.;David R Anderson.;Philip S Wells.;Marc A Rodger.;Susan Solymoss.;Michael J Kovacs.;Lawrence Rudski.;Avi Shimony.;Carole Dennie.;Christopher Rush.;William H Geerts.;Shawn D Aaron.;John T Granton.
来源: Chest. 2017年151卷5期1058-1068页
We aimed to determine the frequency and predictors of exercise limitation after pulmonary embolism (PE) and to assess its association with health-related quality of life (HRQoL) and dyspnea.
72. ICU Telemedicine Program Financial Outcomes.
作者: Craig M Lilly.;Christine Motzkus.;Teresa Rincon.;Shawn E Cody.;Karen Landry.;Richard S Irwin.; .
来源: Chest. 2017年151卷2期286-297页
ICU telemedicine improves access to high-quality critical care, has substantial costs, and can change financial outcomes. Detailed information about financial outcomes and their trends over time following ICU telemedicine implementation and after the addition of logistic center function has not been published to our knowledge.
74. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
作者: Fernando J Martinez.;Klaus F Rabe.;Gary T Ferguson.;Leonardo M Fabbri.;Stephen Rennard.;Gregory J Feldman.;Sanjay Sethi.;Selwyn Spangenthal.;Gregory M Gottschlich.;Roberto Rodriguez-Roisin.;Samir Arora.;Thomas M Siler.;Shahid Siddiqui.;Patrick Darken.;Tracy Fischer.;Andrea Maes.;Michael Golden.;Chad Orevillo.;Colin Reisner.
来源: Chest. 2017年151卷2期340-357页
Long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combinations are a treatment option for patients with COPD who continue to have symptoms despite treatment with a LAMA or a LABA alone. The Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-1) (NCT01854645) and the Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate-to-Very Severe COPD (PINNACLE-2) (NCT01854658) trials investigated the efficacy and safety of a novel glycopyrrolate [GP]/formoterol [FF] 18/9.6-μg (GFF) metered dose inhaler (MDI) formulated using the Co-Suspension Delivery Technology in patients with moderate-to-very severe COPD.
76. Perceived Discrimination Associated With Asthma and Related Outcomes in Minority Youth: The GALA II and SAGE II Studies.
作者: Neeta Thakur.;Nicolas E Barcelo.;Luisa N Borrell.;Smriti Singh.;Celeste Eng.;Adam Davis.;Kelley Meade.;Michael A LeNoir.;Pedro C Avila.;Harold J Farber.;Denise Serebrisky.;Emerita Brigino-Buenaventura.;William Rodriguez-Cintron.;Shannon Thyne.;Jose R Rodriguez-Santana.;Saunak Sen.;Kirsten Bibbins-Domingo.;Esteban Gonzalez Burchard.
来源: Chest. 2017年151卷4期804-812页
Asthma disproportionately affects minority populations and is associated with psychosocial stress such as racial/ethnic discrimination. We aimed to examine the association of perceived discrimination with asthma and poor asthma control in African American and Latino youth.
79. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial.
作者: Marin H Kollef.;Jean-Damien Ricard.;Damien Roux.;Bruno Francois.;Eleni Ischaki.;Zsolt Rozgonyi.;Thierry Boulain.;Zsolt Ivanyi.;Gál János.;Denis Garot.;Firas Koura.;Epaminondas Zakynthinos.;George Dimopoulos.;Antonio Torres.;Wayne Danker.;A Bruce Montgomery.
来源: Chest. 2017年151卷6期1239-1246页
Clinical failures in ventilator-associated pneumonia (VAP) caused by gram-negative bacteria are common and associated with substantial morbidity, mortality, and resource utilization.
80. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
作者: Marilyn K Glassberg.;Julia Minkiewicz.;Rebecca L Toonkel.;Emmanuelle S Simonet.;Gustavo A Rubio.;Darcy DiFede.;Shirin Shafazand.;Aisha Khan.;Marietsy V Pujol.;Vincent F LaRussa.;Lisa H Lancaster.;Glenn D Rosen.;Joel Fishman.;Yolanda N Mageto.;Adam Mendizabal.;Joshua M Hare.
来源: Chest. 2017年151卷5期971-981页
Despite Food and Drug Administration approval of 2 new drugs for idiopathic pulmonary fibrosis (IPF), curative therapies remain elusive and mortality remains high. Preclinical and clinical data support the safety of human mesenchymal stem cells as a potential novel therapy for this fatal condition. The Allogeneic Human Cells (hMSC) in patients with Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER) trial was the first study designed to evaluate the safety of a single infusion of bone marrow-derived mesenchymal stem cells in patients with idiopathic pulmonary fibrosis.
|